Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 HKD | +1.74% | +15.35% | -55.87% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
Evolution of the average Target Price on Alphamab Oncology
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alphamab Oncology
UBS | |
Nomura |
EPS Revisions
- Stock Market
- Equities
- 9966 Stock
- Consensus Alphamab Oncology